Novavax (NVAX) prototype vaccine (NVX-CoV2373) demonstrates broad immune responses including against Omicron and other circulating variants Pre-clinical data demonstrated that boosting with Novavax' ...
Following its emergency authorization last month, just 7,300 doses of Novavax's COVID-19 vaccine have been administered to Americans across the country, newly updated data from the Centers for Disease ...
Americans may soon get a new COVID-19 vaccine option — shots made with a more tried-and-true technology than today’s versions. The big question: Why should they care? After long delays, the Food and ...
That amounts to the most specific timeline to date. Federal officials have said the new shots could arrive around September. CDC Director Mandy Cohen had previously provided a later timeline, telling ...
FDA authorization of Novavax's vaccine was delayed for weeks as the agency reviewed changes to the company's manufacturing process. The Novavax shot is based on more conventional protein technology ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. American adults who haven't yet gotten vaccinated against COVID-19 should consider a new option ...
Shares of Novavax have come under renewed scrutiny as analysts update their fair value estimates in light of recent strategic shifts. The consensus analyst price target for Novavax stock has edged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback